Samsung Bioepis Biosimilars Update

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

  • According to Business Wire, on September 12, 2016, Samsung Bioepis announced that it has added Canada to its growing list of jurisdictions in which it has received regulatory approval for its biosimilar of Amgen’s Enbrel® (etanercept).  The biosimilar will be marketed in Canada under the brand Brenzys® as a treatment for rheumatoid arthritis and ankylosing spondylitis.
  • According to The Korea Times, earlier this month, Samsung Bioepis launched its biosimilar of Janssen’s Remicade® (infliximab) in the United Kingdom.  Samsung Bioepis received European regulatory approval for its biosimilar, under the brand Flixabi™, this past May.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide